首页> 外文期刊>Travel medicine and infectious disease >Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.
【24h】

Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.

机译:丝状病毒的出现和疫苗的开发:旅行医疗保健从业者的观点。

获取原文
获取原文并翻译 | 示例
           

摘要

Recent case reports of viral hemorrhagic fever in Europe and the United States have raised concerns about the possibility for increased importation of filoviruses to non-endemic areas. This emerging threat is concerning because of the increase in global air travel and the rise of tourism in central and eastern Africa and the greater dispersion of military troops to areas of infectious disease outbreaks. Marburg viruses (MARV) and Ebola viruses (EBOV) have been associated with outbreaks of severe hemorrhagic fever involving high mortality (25-90% case fatality rates). First recognized in 1967 and 1976 respectively, subtypes of MARV and EBOV are the only known viruses of the Filoviridae family, and are among the world's most virulent pathogens. This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine.
机译:在欧洲和美国,最近的病毒性出血热病例报告引起了人们对向非流行地区增加丝状病毒进口的可能性的担忧。由于全球航空旅行的增加和中非和东部非洲旅游业的增加,以及军事部队向传染病暴发地区的更大分散,这种新出现的威胁令人担忧。马尔堡病毒(MARV)和埃博拉病毒(EBOV)与严重出血热的爆发有关,涉及高死亡率(25-90%病死率)。 MARV和EBOV的亚型分别于1967年和1976年首次被发现,是费氏病毒科唯一已知的病毒,并且是世界上最强毒的病原体之一。本文重点介绍与旅行医疗保健从业人员有关的信息,包括丝状病毒感染的流行病学和临床特征以及开发丝状病毒疫苗的努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号